Cargando…

Chemoimmunotherapy as long-term maintenance therapy for cancer

Homeostatic immune regulatory mechanisms can mediate premature termination of therapy-induced antitumor T-effector cell responses. Administration of cyclophosphamide (CY) prior to intratumoral IL-12 and GM-CSF delivery blocked post-treatment T-suppressor cell rebound via elimination of the pre-exist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Egilmez, Nejat K., Harden, Jamie L., Rowswell-Turner, Rachael B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382905/ https://www.ncbi.nlm.nih.gov/pubmed/22754788

Ejemplares similares

MAPK signaling regulates the efficacy of chemoimmunotherapy
por: Ghiringhelli, François
Publicado: (2022)

Chemoimmunotherapy for advanced gastrointestinal carcinomas: A successful combination of gene therapy and cyclophosphamide
por: Malvicini, Mariana, et al.
Publicado: (2012)

Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
por: Thibaudin, Marion, et al.
Publicado: (2023)

Modulating gut immunity and neoplasia with oral cytokine adjuvants
por: Ozbilge, Hatice, et al.
Publicado: (2015)

Telomere maintenance: regulating hTERC fate through RNA modifications
por: Lirussi, Lisa, et al.
Publicado: (2019)

Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy
por: Lu, Yong, et al.
Publicado: (2014)

ImmTACs: Novel bi-specific agents for targeted cancer therapy
por: Oates, Joanne, et al.
Publicado: (2013)

Oncogenic long noncoding RNA FAL1 in human cancer
por: Zhong, Xiaomin, et al.
Publicado: (2015)

Tuning protein synthesis for cancer therapy
por: Knight, John R. P., et al.
Publicado: (2021)

β-endorphin neuron transplantation: A possible novel therapy for cancer prevention
por: Zhang, Changqing, et al.
Publicado: (2012)

Cancer testis antigens: A new paradigm for cancer therapy
por: Suri, Anil, et al.
Publicado: (2012)

Trial watch: Immunostimulatory cytokines in cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2014)

GD2 and GD3 synthase: novel drug targets for cancer therapy
por: Sphyris, Nathalie, et al.
Publicado: (2015)

How to develop better screens for anti-cancer therapies?
por: Hong, Michelle, et al.
Publicado: (2012)

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
por: Aranda, Fernando, et al.
Publicado: (2014)

Sustaining the spindle assembly checkpoint to improve cancer therapy
por: Visconti, Roberta, et al.
Publicado: (2015)

Toward a rational design of combination therapy in cancer
por: Doucey, Marie-Agnès, et al.
Publicado: (2015)

Local immunomodulation for cancer therapy: Providing treatment where needed
por: Fransen, Marieke F, et al.
Publicado: (2013)

Application of iPS cell-derived macrophages to cancer therapy
por: Senju, Satoru, et al.
Publicado: (2014)

Immunological profiling as a means to invigorate personalized cancer therapy
por: Hegmans, Joost PJJ, et al.
Publicado: (2013)

BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
por: Herr, Ricarda, et al.
Publicado: (2015)

SAMHD1 is a barrier to antimetabolite-based cancer therapies
por: Rudd, Sean G., et al.
Publicado: (2017)

Battling the two-headed dragon of prostate cancer targeted therapy
por: Wilkinson, Scott, et al.
Publicado: (2020)

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013)

The double-edge sword effect of anti-CD73 cancer therapy
por: Stagg, John
Publicado: (2012)

Why should we need the gut microbiota to respond to cancer therapies?
por: Viaud, Sophie, et al.
Publicado: (2014)

In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer
por: Thakur, Archana, et al.
Publicado: (2015)

Crack the state of silence: Tune the depth of cellular quiescence for cancer therapy
por: Fujimaki, Kotaro, et al.
Publicado: (2017)

Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers
por: Lebret, Thierry, et al.
Publicado: (2015)

Endogenous and exogenous glucocorticoids abolish the efficacy of immune-dependent cancer therapies
por: Ma, Yuting, et al.
Publicado: (2019)

Reviving the role of MET in liver cancer therapy and vaccination: an autophagic perspective
por: Huang, Xing, et al.
Publicado: (2020)

Rethinking the role of myeloid-derived suppressor cells in adoptive T-cell therapy for cancer
por: Arina, Ainhoa
Publicado: (2014)

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
por: Issa-Nummer, Yasmin, et al.
Publicado: (2014)

Personalized medicine for cancer therapy: Lessons learned from tumor-associated antigens
por: Scanlon, Christina Springstead, et al.
Publicado: (2013)

BORA-dependent PLK1 regulation: A new weapon for cancer therapy?
por: Cirillo, Luca, et al.
Publicado: (2016)

ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
por: Lei, Jonathan T., et al.
Publicado: (2018)

Dual role of N-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy
por: Asaka, Ryoichi, et al.
Publicado: (2019)

BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy
por: Sancho, Mónica, et al.
Publicado: (2021)

Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
por: Tomita, Yusuke, et al.
Publicado: (2013)

What does not kill you makes you stronger: surviving anti-cancer therapies by cytoskeletal remodeling and Myosin II reactivation
por: Orgaz, Jose L, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2eerv09f564h987aiml2ap9snf